In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

APT Pharmaceuticals, Inc.

http://www.aptbio.com/

Latest From APT Pharmaceuticals, Inc.

Chinese Bioventures Grab $860m In Latest Public Listing, Financing Dash

Accelerated initial public listings, multi-million dollar deals and hot investment fund influxes fuel an already record-setting July for biotech fundraising in China.

China Financing

Mirati Marks Another Milestone With Adagrasib

Mirati executives are still being pushed to defend the safety profile for the KRAS G12C inhibitor adagrasib, which has been seen as a potential disadvantage relative to Amgen’s Lumakras.

FDA Business Strategies

Zai Lab Joins Latest Oncology Race With Mirati KRAS Deal

Hot on the heels of a high-profile US approval, Chinese biotechs from BeiGene, Betta to Zai Lab and lesser-known InventisBio, are racing to get their KRAS-targeting cancer drugs launched. Zai Lab, however, hopes to win with a potential best-in-class contender from its partner Mirati of the US.

China Commercial

Incyte Taps Wide-Open Vitiligo Market With Positive Ruxolitinib Results

Dermatologists have compared the current market for vitiligo to that of psoriasis 30 years ago, which grew from one with a dearth of therapies to one worth about $8bn.

Dermatology Immune Disorders
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
UsernamePublicRestriction

Register